Intralytix Signs Multiple Project Collaboration Agreement With Procter & Gamble

BALTIMORE--(BUSINESS WIRE)-- Intralytix, Inc., announced today that it has entered into a Multiple Project Collaboration Agreement (“MPCA”) with The Procter & Gamble Company (NYSE:PG).

“The MPCA sets the stage for Intralytix and P&G to collaborate on the development of bacteriophage (or phage) based technology for a range of applications,” stated John Woloszyn, Intralytix’s CEO. “Our phage-based technology is all natural and environmentally friendly and we look forward to this collaboration bringing forth new innovations,” Mr. Woloszyn added.

Mr. Woloszyn also noted that the company already has two FDA/USDA approved phage-based products on the market: ListShield™, effective at substantially reducing or eliminating Listeria monocytogenes on food products, and EcoShield™, effective at substantially reducing or eliminating E. coli O157:H7 on red meat intended for grinding.

Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health and human therapeutics and probiotics.

Safety by Nature
Web site: www.Intralytix.com
YouTube: http://www.youtube.com/watch?v=fFoo1OVa11E
Food Safety Solutions Blog: http://phagesolutions.blogspot.com/
Twitter: http://twitter.com/intralytix



CONTACT:

Intralytix, Inc.
Mr. John Woloszyn, 443-275-9694
[email protected]
or
Dr. Barbara Miller, 513-622-4350
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Retail  Food/Beverage  General Health

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.